Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion

NCT05850520 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05850520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05850520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
May 15, 2023
Completion date
May 27, 2025
Enrollment
892 (actual)
Sites
273

Conditions

As the registry lists them; a condition with its own page is linked.

macular edema secondary to retinal vein occlusion